trans·gene

(trăns′jēn′, trănz′-)

A gene used in transgenesis.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

transgene

(ˈtrænzˌdʒiːn)

(Genetics) genetics a gene that is transferred from an organism of one species to an organism of another species by genetic engineering

Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014

ThesaurusAntonymsRelated WordsSynonymsLegend:

Noun

transgene - an exogenous gene introduced into the genome of another organism

cistron, gene, factor - (genetics) a segment of DNA that is involved in producing a polypeptide chain; it can include regions preceding and following the coding DNA as well as introns between the exons; it is considered a unit of heredity; "genes were formerly called factors"

Mentioned in

References in periodicals archive

- French biotechnology company Transgene (PAR: TNG) this week provided an update on the interim futility analysis of the PHOCUS study of Pexa-Vec in liver cancer, the company said.

Transgene Provides an Update After the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer

The ability to safely re-dose AAV should help achieve therapeutic benefit in patients who are under-dosed; it should also help restore transgene expression in patients, particularly growing pediatric patients, who may lose expression over time.

Selecta Biosciences, AskBio announce strategic partnership for gene therapy

France-based Transgene has announced that the independent Data Monitoring Committee (IDMC) for the PHOCUS study of Pexa-Vec in Liver Cancer has completed a planned interim futility analysis, it was reported yesterday.

Transgene reports developments in Pexa-Vec Liver Cancer study

Biotech company Transgene (Paris:TNG) said on Monday that it has dosed the last patient under the Phase 2 trial evaluating TG4010 in combination with Opdivo (nivolumab) and chemotherapy as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC).

Transgene begins treatment of last lung cancer patient under the Phase 2 trial of TG4010 in combination with Opdivo (nivolumab)

TOKYO, Oct 30, 2018 - (JCN Newswire) - NEC Corporation (TSE: 6701) and Transgene today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid cancers.

NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene's myvac Platform

21 August 2018 - French virus-based immunotherapies developer Transgene (PAR: TNG) has closed transactions signed with Chinese drugmaker Tasly Biopharmaceuticals.

Transgene Closes USD 48m Sale of the Greater China Rights of TG6002 and TG1050 to Tasly Biopharmaceuticals

Here we isolated a pure population of osteoblasts from intramembranous bone of neonatal mice carrying both Osx1-GFP::Cre and Oct4-EGFP transgenes. Daily monitoring of the reprogramming process revealed initial silencing of Osx1-GFP::Cre transgene expression followed by late activation of Oct4-EGFP expression when iPS cells were formed with comparable reprogramming efficiency as skin fibroblast-derived iPS cells.

Reprogramming of Mouse Calvarial Osteoblasts into Induced Pluripotent Stem Cells

This plasmid, carrying this intended "transgene," would be introduced into a tissue culture "packaging cell line" that has been engineered to also express the required AAV viral capsid proteins and the required "helper virus" genes.

Gene therapy I: AAV as viral vector

Transgene and Randox have entered into a collaboration to combine their technologies and develop multifunctional oncolytic immunotherapies.

TRANSGENE AND RANDOX DEVELOP OV'S FOR SOLID TUMORS

Servier and Transgene have signed a research agreement on the application of viral vectorization technology for the production of allogenic CAR-T cell therapies.

SERVIER AND TRANSGENE SIGN RESEARCH AGREEMENT

Recently developed transgene delivery techniques and genome editing tools will advance biotechnology research areas much more rapidly.

Efficient transgene expression system using a cumate-inducible promoter and Cre-loxP recombination in avian cells